COMMON WARTS (VERRUCA VULGARIS)
Clinical trials for COMMON WARTS (VERRUCA VULGARIS) explained in plain language.
Never miss a new study
Get alerted when new COMMON WARTS (VERRUCA VULGARIS) trials appear
Sign up with your email to follow new studies for COMMON WARTS (VERRUCA VULGARIS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Wart war: vitamin D3 injections take on antiviral drug in new trial
⭐️ CURE ⭐️ Recruiting nowThis study tests whether injecting vitamin D3 or the antiviral drug acyclovir directly into warts can clear them. Forty people aged 12 and older with common, plantar, flat, or nail warts will receive up to 4 injections every 2 weeks. The main goal is to see which treatment leads …
Matched conditions: COMMON WARTS (VERRUCA VULGARIS)
Phase: PHASE4 • Sponsor: Riphah International University • Aim: ⭐️ CURE ⭐️
Last updated May 11, 2026 20:49 UTC
-
New hope for stubborn warts: extended treatment shows promise
Disease control Recruiting nowThis study follows people who already took part in earlier trials for common warts. They can receive up to 4 more treatments with YCANTH, a liquid applied to each wart every 21 days. The goal is to see if the treatment is safe and can clear all warts over about a year. Around 600…
Matched conditions: COMMON WARTS (VERRUCA VULGARIS)
Phase: PHASE3 • Sponsor: Verrica Pharmaceuticals Inc. • Aim: Disease control
Last updated May 17, 2026 05:47 UTC
-
New gel could zap away common warts
Disease control Recruiting nowThis study tests a gel called YCANTH on common warts caused by HPV. About 300 people aged 2 and older will apply the gel to their warts to see if it clears them completely by day 84. The goal is to find a safe and effective treatment for warts on the body.
Matched conditions: COMMON WARTS (VERRUCA VULGARIS)
Phase: PHASE3 • Sponsor: Verrica Pharmaceuticals Inc. • Aim: Disease control
Last updated May 17, 2026 05:31 UTC